Gut microbiome in immuno-oncology: potential for clinical exploitation
Best Practice & Research Clinical Gastroenterology · 2026-08 · 83 · 102143
DOI: 10.1016/j.bpg.2026.102143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-08. Verfasst von Ernesto Margarita und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, European Research Council, Joint Programming Initiative on Antimicrobial Resistance.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of multiple malignancies, yet durable clinical benefit remains limited to a subset of patients, while immune-related adverse events still represent a major therapeutic challenge. Over the past decade, compelling evidence has established the gut microbiota as a key host determinant of both the efficacy and toxicity of cancer immunotherapy. Given its profound diversity and plasticity, as well as its impact on systemic immunity, gut commensals are now considered as both a promising predictive biomarker of response and a potentially actionable therapeutic target. As a result, different microbiota-informed approaches are being explored for precision immune-oncology. Specifically, emerging biomarker strategies are moving beyond single bacterial taxa toward ecological and functional microbial signatures with improved reproducibility across patient cohorts. At the same time, therapeutic modulation of the gut microbiome, through dietary interventions, prebiotics, probiotics, and fecal microbiota transplantation, is being actively investigated to enhance responsiveness to ICIs and mitigate immune-related adverse events. In this review, we discuss the biological mechanisms linking gut microbiota and immunotherapy, evaluate its role as biomarker and therapeutic target, and address the current challenges that need to be overcome to integrate microbiota into precision immune-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy.
- Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy; Department of Medical and Surgical Sciences, UOC CEMAD Centro Malattie dell'Apparato D…
Förderung
- Ministero dell’Istruzione, dell’Università e della Ricerca
- European Research Council
- Joint Programming Initiative on Antimicrobial Resistance
- Ministero della Salute
- Fondazione Roma
- Seerave Foundation
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Margarita, E., Saito, K., Bisegna, P., Ferrari, M., Valeriani, E., Guerrieri, M., Funaro, B., Feliciani, D., Gasbarrini, A., Porcari, S., & Ianiro, G. (2026). Gut microbiome in immuno-oncology: potential for clinical exploitation. Best Practice & Research Clinical Gastroenterology, 83, 102143. https://doi.org/10.1016/j.bpg.2026.102143
Vancouver
Margarita E, Saito K, Bisegna P, Ferrari M, Valeriani E, Guerrieri M, et al. Gut microbiome in immuno-oncology: potential for clinical exploitation. Best Practice & Research Clinical Gastroenterology. 2026;83:102143. doi:10.1016/j.bpg.2026.102143
BibTeX
@article{Margarita2026,
author = {Margarita, Ernesto and Saito, Kosei and Bisegna, Piergiorgio and Ferrari, Margherita and Valeriani, Eleonora and Guerrieri, Marzia and Funaro, Barbara and Feliciani, Daniela and Gasbarrini, Antonio and Porcari, Serena and Ianiro, Gianluca},
title = {Gut microbiome in immuno-oncology: potential for clinical exploitation},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2026},
volume = {83},
pages = {102143},
doi = {10.1016/j.bpg.2026.102143}
}
EUVIMED